Signadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosedTV
Taiho Ventures
Activity from announced rounds
Activity in this selectionnrw-venture-f5757e51
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $197.1M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionCrossbow Therapeutics
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
$77MSeries B
Role not disclosedEpiBiologics
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
$107MSeries B
Role not disclosed